309 results on '"Wolfe MS"'
Search Results
2. Investigating Rate Integrity in Convention Cities
- Author
-
Kara Wolfe Ms and Carl A. Boger
- Subjects
Convention ,Product (business) ,business.industry ,Reservation ,For profit ,The Internet ,General Medicine ,Business ,Yield management ,Marketing - Abstract
Yield Management (YM) is the utilization of tactics to align a consumer product within the market for profit maximization. By evaluating how rates are quoted to consumers, the effectiveness of YM tactics can be delineated. This study compared central reservation (CR) telephone and Internet room rates by city. The CR centers for full-service hotels in 19 different cities were contacted by telephone to request a room. The CR rates were compared to rates obtained from the hotels' Internet sites. The data analysis found significant differences in reservation rates by city and by size of the lodging property. Hoteliers can use the information to evaluate the effectiveness of their YM systems.
- Published
- 2001
3. A presenilin dimer at the core of the gamma-secretase enzyme: insights from parallel analysis of Notch1 and APP proteolysis
- Author
-
Schroeter, EH, Ilagan, MXG, Brunkan, AL, Hećimović, Silva, Li, Y-M, Xu, M, Lewis, HD, Saxena, MT, De Strooper, B, Coonrod, A, Tomita, T, Iwatsubo, T, Moore, CL, Shearman, M, Goate, A, Wolfe, MS, and Kopan, R
- Subjects
Alzheimer's disease ,Dementia ,Gamma-secretase ,Neurodegeneration ,Presenilin - Abstract
Notch receptors and the amyloid precursor protein are type I membrane proteins that are proteolytically cleaved within their transmembrane domains by a presenilin (PS)-dependent γ -secretase activity. In both proteins, two peptide bonds are hydrolyzed: one near the inner leaflet and the other in the middle of the transmembrane domain. Under saturating conditions the substrates compete with each other for proteolysis, but not for binding to PS. At least some Alzheimer's disease-causing PS mutations reside in proteins possessing low catalytic activity. We demonstrate (i) that differentially tagged PS molecules coimmunoprecipitate, and (ii) that PS N-terminal fragment dimers exist by using a photoaffinity probe based on a transition state analog γ -secretase inhibitor. We propose that γ -secretase contains a PS dimer in its catalytic core, that binding of substrate is at a site separate from the active site, and that substrate is cleaved at the interface of two PS molecules.
- Published
- 2003
4. Differentialin vivo expression of collagenase messenger RNA in synovium and cartilage. Quantitative comparison with stromelysin messenger rna levels in human rheumatoid arthritis and osteoarthritis patients and in two animal models of acute inflammatory arthritis
- Author
-
Wolfe Ms, Gloria C. ,, primary, Macnaul Bs, Karen L. ,, additional, Buechel, Frederick F., additional, Mcdonnell, Joseph, additional, Hoerrner Bs, Lori A. ,, additional, Lark, Michael W., additional, Moore, Vernon L., additional, and Hutchinson, Nancy I., additional
- Published
- 1993
- Full Text
- View/download PDF
5. Update on travel medicine.
- Author
-
Armitage KB and Wolfe MS
- Abstract
As tourists continue to enter remote areas, you need to prepare them with the most up-to-date information on vaccinations, malaria prophylaxis, and other vital precautions. The job may not be over until long after the patient returns home. [ABSTRACT FROM AUTHOR]
- Published
- 2003
6. Travel medicine update: with more patients traveling to remote areas, you need quick access to the latest information on outbreaks and vaccine use.
- Author
-
Young MG, Armitage KB, Johnson WD, and Wolfe MS
- Published
- 2001
7. Differential in vivo expression of collagenase messenger RNA in synovium and cartilage. Quantitative comparison with stromelysin messenger rna levels in human rheumatoid arthritis and osteoarthritis patients and in two animal models of acute inflammatory arthritis
- Author
-
Wolfe Ms, Gloria C. ,, Macnaul Bs, Karen L. ,, Buechel, Frederick F., Mcdonnell, Joseph, Hoerrner Bs, Lori A. ,, Lark, Michael W., Moore, Vernon L., and Hutchinson, Nancy I.
- Published
- 1993
- Full Text
- View/download PDF
8. Travel infections: the road to good health.
- Author
-
Johnson WD Jr., Wiest PJ, and Wolfe MS
- Abstract
Exotic ports of call now pose new problems, such as leishmaniasis, and add new twists to old ones, such as drug-resistant malaria. These preventive tips will help your patients keep illness off the itinerary. [ABSTRACT FROM AUTHOR]
- Published
- 1994
9. Management of the Traveler to Exotic Places
- Author
-
Wolfe Ms
- Subjects
medicine.medical_specialty ,Immunization ,business.industry ,Family medicine ,Immunology ,Public Health, Environmental and Occupational Health ,medicine ,Developing country ,Disease prevention ,General Medicine ,medicine.disease ,business ,Malaria - Published
- 1976
10. Chloroquine-resistant falciparum malaria in northern Malawi
- Author
-
Breman Jg, Ainsworth B, Teklehaimanot A, Wolfe Ms, and Patchen Lc
- Subjects
Adult ,Male ,Malawi ,Tetracycline ,Plasmodium falciparum ,Amodiaquine ,Microbial Sensitivity Tests ,Chloroquine ,Virology ,parasitic diseases ,Sulfadoxine ,medicine ,Humans ,Doxycycline ,Quinine ,biology ,business.industry ,Drug Resistance, Microbial ,biology.organism_classification ,medicine.disease ,Malaria ,Drug Combinations ,Infectious Diseases ,Pyrimethamine ,Parasitology ,business ,medicine.drug - Abstract
An American Peace Corps volunteer contracted chloroquine-resistant Plasmodium falciparum malaria while serving in Malawi and taking regular chloroquine prophylaxis. Resistance was confirmed by in vitro testing of his parasites for chloroquine and pyrimethamine. The possibility of Fansidar-resistant falciparum malaria was also suggested in this case. American expatriates residing in or traveling to Malawi are advised to either take both chloroquine and Fansidar, or alternatively amodiaquine or doxycycline alone. Any breakthrough of slide-proven falciparum malaria in these individuals should be seriously suspected to be chloroquine- and Fansidar-resistant malaria, and should be treated with quinine and tetracycline.
- Published
- 1985
11. Contaminated Laetrile: A Health Hazard
- Author
-
Wolfe Ms
- Subjects
Containment (computer programming) ,business.industry ,Forensic engineering ,Medicine ,General Medicine ,business - Published
- 1977
12. Letter: Clindamycin-associated colitis
- Author
-
Wolfe Ms
- Subjects
medicine.medical_specialty ,Adolescent ,business.industry ,Clindamycin ,General Medicine ,Colitis ,medicine.disease ,Gastroenterology ,Internal medicine ,Acne Vulgaris ,medicine ,Humans ,Female ,business ,medicine.drug - Published
- 1974
13. Selective amyloid-beta lowering agents.
- Author
-
Wolfe MS and Wolfe, Michael S
- Abstract
The amyloid-beta peptide (Abeta), implicated in the pathogenesis of Alzheimer's disease (AD), is produced through sequential proteolysis of the Abeta precursor protein (APP) by beta- and gamma-secretases. Thus, blocking either of these two proteases, directly or indirectly, is potentially worthwhile toward developing AD therapeutics. beta-Secretase is a membrane-tethered pepsin-like aspartyl protease suitable for structure-based design, whereas gamma-secretase is an unusual, heterotetrameric membrane-embedded aspartyl protease. While gamma-secretase inhibitors entered clinical trials first due to their superior pharmacological properties (for example, brain penetration) over beta-secretase inhibitors, it has since become clear that gamma-secretase inhibitors can cause mechanism-based toxicities owing to interference with the proteolysis of another gamma-secretase substrate, the Notch receptor. Strategies for targeting Abeta production at the gamma-secretase level without blocking Notch signalling will be discussed. Other strategies utilizing cell-based screening have led to the identification of novel Abeta lowering agents that likewise leave Notch proteolysis intact. The mechanism by which these agents lower Abeta is unknown, but these compounds may ultimately reveal new targets for AD therapeutics. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
14. Seasonal care. Update on travel medicine.
- Author
-
Armitage KB and Wolfe MS
- Abstract
As tourists continue to enter remote areas, you need to prepare them with the most up-to-date information on vaccinations, malaria prophylaxis, and other vital precautions. The job may not be over until long after the patient returns home. [ABSTRACT FROM AUTHOR]
- Published
- 2003
15. Alzheimer-mutant γ-secretase complexes stall amyloid β-peptide production.
- Author
-
Arafi P, Devkota S, Maesako M, and Wolfe MS
- Abstract
Missense mutations in the amyloid precursor protein (APP) and presenilin-1 (PSEN1) cause early-onset familial Alzheimer's disease (FAD) and alter proteolytic production of secreted 38-to-43-residue amyloid β-peptides (Aβ) by the PSEN1-containing γ-secretase complex, ostensibly supporting the amyloid hypothesis of pathogenesis. However, proteolysis of APP substrate by γ-secretase is processive, involving initial endoproteolysis to produce long Aβ peptides of 48 or 49 residues followed by carboxypeptidase trimming in mostly tripeptide increments. We recently reported evidence that FAD mutations in APP and PSEN1 cause deficiencies in early steps in processive proteolysis of APP substrate C99 and that this results from stalled γ-secretase enzyme-substrate and/or enzyme-intermediate complexes. These stalled complexes triggered synaptic degeneration in a C. elegans model of FAD independently of Aβ production. Here we conducted full quantitative analysis of all proteolytic events on APP substrate by γ-secretase with six additional PSEN1 FAD mutations and found that all six are deficient in multiple processing steps. However, only one of these (F386S) was deficient in certain trimming steps but not in endoproteolysis. Fluorescence lifetime imaging microscopy in intact cells revealed that all six PSEN1 FAD mutations lead to stalled γ-secretase enzyme-substrate/intermediate complexes. The F386S mutation, however, does so only in Aβ-rich regions of the cells, not in C99-rich regions, consistent with the deficiencies of this mutant enzyme only in trimming of Aβ intermediates. These findings provide further evidence that FAD mutations lead stalled and stabilized γ-secretase enzyme-substrate and/or enzyme-intermediate complexes and are consistent with the stalled process rather than the products of γ-secretase proteolysis as the pathogenic trigger.
- Published
- 2024
- Full Text
- View/download PDF
16. Familial Alzheimer mutations stabilize synaptotoxic γ-secretase-substrate complexes.
- Author
-
Devkota S, Zhou R, Nagarajan V, Maesako M, Do H, Noorani A, Overmeyer C, Bhattarai S, Douglas JT, Saraf A, Miao Y, Ackley BD, Shi Y, and Wolfe MS
- Subjects
- Animals, Amyloid Precursor Protein Secretases genetics, Amyloid beta-Peptides, Cryoelectron Microscopy, Mutation genetics, Caenorhabditis elegans genetics, Molecular Dynamics Simulation, Alzheimer Disease genetics
- Abstract
Mutations that cause familial Alzheimer's disease (FAD) are found in amyloid precursor protein (APP) and presenilin, the catalytic component of γ-secretase, that together produce amyloid β-peptide (Aβ). Nevertheless, whether Aβ is the primary disease driver remains controversial. We report here that FAD mutations disrupt initial proteolytic events in the multistep processing of APP substrate C99 by γ-secretase. Cryoelectron microscopy reveals that a substrate mimetic traps γ-secretase during the transition state, and this structure aligns with activated enzyme-substrate complex captured by molecular dynamics simulations. In silico simulations and in cellulo fluorescence microscopy support stabilization of enzyme-substrate complexes by FAD mutations. Neuronal expression of C99 and/or presenilin-1 in Caenorhabditis elegans leads to synaptic loss only with FAD-mutant transgenes. Designed mutations that stabilize the enzyme-substrate complex and block Aβ production likewise led to synaptic loss. Collectively, these findings implicate the stalled process-not the products-of γ-secretase cleavage of substrates in FAD pathogenesis., Competing Interests: Declaration of interests The authors declare no competing interests., (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
17. γ-Secretase: once and future drug target for Alzheimer's disease.
- Author
-
Wolfe MS
- Subjects
- Humans, Amyloid Precursor Protein Secretases, Amyloid beta-Peptides, Alzheimer Disease drug therapy
- Published
- 2024
- Full Text
- View/download PDF
18. Molecular Dynamics Activation of γ-Secretase for Cleavage of the Notch1 Substrate.
- Author
-
Do HN, Malvankar SR, Wolfe MS, and Miao Y
- Subjects
- Amyloid beta-Protein Precursor genetics, Amyloid beta-Protein Precursor metabolism, Receptors, Notch, Cell Membrane metabolism, Presenilin-1 genetics, Presenilin-1 metabolism, Amyloid Precursor Protein Secretases metabolism, Molecular Dynamics Simulation
- Abstract
γ-Secretase is an intramembrane aspartyl protease complex that cleaves the transmembrane domain of over 150 peptide substrates, including amyloid precursor protein (APP) and the Notch family of receptors, via two conserved aspartates D257 and D385 in the presenilin-1 (PS1) catalytic subunit. However, while the activation of γ-secretase for cleavage of APP has been widely studied, the cleavage of Notch by γ-secretase remains poorly explored. Here, we combined Gaussian accelerated molecular dynamics (GaMD) simulations and mass spectrometry (MS) analysis of proteolytic products to present the first dynamic models for cleavage of Notch by γ-secretase. MS showed that γ-secretase cleaved the WT Notch at Notch residue G34, while cleavage of the L36F mutant Notch occurred at Notch residue C33. Initially, we prepared our simulation systems starting from the cryoEM structure of Notch-bound γ-secretase (PDB: 6IDF) and failed to capture the proper cleavages of WT and L36F Notch by γ-secretase. We then discovered an incorrect registry of the Notch substrate in the PS1 active site through alignment of the experimental structure of Notch-bound (PDB: 6IDF) and APP-bound γ-secretase (PDB: 6IYC). Every residue of the APP substrate was systematically mutated to the corresponding Notch residue to prepare a resolved model of Notch-bound γ-secretase complexes. GaMD simulations of the resolved model successfully captured γ-secretase activation for proper cleavages of both WT and L36F mutant Notch. Our findings presented here provided mechanistic insights into the structural dynamics and enzyme-substrate interactions required for γ-secretase activation for cleavage of Notch and other substrates.
- Published
- 2023
- Full Text
- View/download PDF
19. A neurodegeneration checkpoint mediated by REST protects against the onset of Alzheimer's disease.
- Author
-
Aron L, Qiu C, Ngian ZK, Liang M, Drake D, Choi J, Fernandez MA, Roche P, Bunting EL, Lacey EK, Hamplova SE, Yuan M, Wolfe MS, Bennett DA, Lee EA, and Yankner BA
- Subjects
- Animals, Humans, Mice, Aging metabolism, Amyloid beta-Peptides metabolism, Disease Models, Animal, Mice, Transgenic, tau Proteins metabolism, Alzheimer Disease genetics, Alzheimer Disease prevention & control, Alzheimer Disease metabolism, Cognitive Dysfunction genetics, Cognitive Dysfunction prevention & control
- Abstract
Many aging individuals accumulate the pathology of Alzheimer's disease (AD) without evidence of cognitive decline. Here we describe an integrated neurodegeneration checkpoint response to early pathological changes that restricts further disease progression and preserves cognitive function. Checkpoint activation is mediated by the REST transcriptional repressor, which is induced in cognitively-intact aging humans and AD mouse models at the onset of amyloid β-protein (Aβ) deposition and tau accumulation. REST induction is mediated by the unfolded protein response together with β-catenin signaling. A consequence of this response is the targeting of REST to genes involved in key pathogenic pathways, resulting in downregulation of gamma secretase, tau kinases, and pro-apoptotic proteins. Deletion of REST in the 3xTg and J20 AD mouse models accelerates Aβ deposition and the accumulation of misfolded and phosphorylated tau, leading to neurodegeneration and cognitive decline. Conversely, viral-mediated overexpression of REST in the hippocampus suppresses Aβ and tau pathology. Thus, REST mediates a neurodegeneration checkpoint response with multiple molecular targets that may protect against the onset of AD., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
20. Emerging structures and dynamic mechanisms of γ-secretase for Alzheimer's disease.
- Author
-
Miao Y and Wolfe MS
- Abstract
γ-Secretase, called "the proteasome of the membrane," is a membrane-embedded protease complex that cleaves 150+ peptide substrates with central roles in biology and medicine, including amyloid precursor protein and the Notch family of cell-surface receptors. Mutations in γ-secretase and amyloid precursor protein lead to early-onset familial Alzheimer's disease. γ-Secretase has thus served as a critical drug target for treating familial Alzheimer's disease and the more common late-onset Alzheimer's disease as well. However, critical gaps remain in understanding the mechanisms of processive proteolysis of substrates, the effects of familial Alzheimer's disease mutations, and allosteric modulation of substrate cleavage by γ-secretase. In this review, we focus on recent studies of structural dynamic mechanisms of γ-secretase. Different mechanisms, including the "Fit-Stay-Trim," "Sliding-Unwinding," and "Tilting-Unwinding," have been proposed for substrate proteolysis of amyloid precursor protein by γ-secretase based on all-atom molecular dynamics simulations. While an incorrect registry of the Notch1 substrate was identified in the cryo-electron microscopy structure of Notch1-bound γ-secretase, molecular dynamics simulations on a resolved model of Notch1-bound γ-secretase that was reconstructed using the amyloid precursor protein-bound γ-secretase as a template successfully captured γ-secretase activation for proper cleavages of both wildtype and mutant Notch, being consistent with biochemical experimental findings. The approach could be potentially applied to decipher the processing mechanisms of various substrates by γ-secretase. In addition, controversy over the effects of familial Alzheimer's disease mutations, particularly the issue of whether they stabilize or destabilize γ-secretase-substrate complexes, is discussed. Finally, an outlook is provided for future studies of γ-secretase, including pathways of substrate binding and product release, effects of modulators on familial Alzheimer's disease mutations of the γ-secretase-substrate complexes. Comprehensive understanding of the functional mechanisms of γ-secretase will greatly facilitate the rational design of effective drug molecules for treating familial Alzheimer's disease and perhaps Alzheimer's disease in general., (Copyright © 2025 Copyright: © 2025 Neural Regeneration Research.)
- Published
- 2025
- Full Text
- View/download PDF
21. Effects of presenilin-1 familial Alzheimer's disease mutations on γ-secretase activation for cleavage of amyloid precursor protein.
- Author
-
Do HN, Devkota S, Bhattarai A, Wolfe MS, and Miao Y
- Subjects
- Humans, Amyloid Precursor Protein Secretases genetics, Amyloid Precursor Protein Secretases metabolism, Mutation, Alzheimer Disease genetics, Alzheimer Disease metabolism, Amyloid beta-Protein Precursor genetics, Amyloid beta-Protein Precursor metabolism, Presenilin-1 genetics, Presenilin-1 metabolism
- Abstract
Presenilin-1 (PS1) is the catalytic subunit of γ-secretase which cleaves within the transmembrane domain of over 150 peptide substrates. Dominant missense mutations in PS1 cause early-onset familial Alzheimer's disease (FAD); however, the exact pathogenic mechanism remains unknown. Here we combined Gaussian accelerated molecular dynamics (GaMD) simulations and biochemical experiments to determine the effects of six representative PS1 FAD mutations (P117L, I143T, L166P, G384A, L435F, and L286V) on the enzyme-substrate interactions between γ-secretase and amyloid precursor protein (APP). Biochemical experiments showed that all six PS1 FAD mutations rendered γ-secretase less active for the endoproteolytic (ε) cleavage of APP. Distinct low-energy conformational states were identified from the free energy profiles of wildtype and PS1 FAD-mutant γ-secretase. The P117L and L286V FAD mutants could still sample the "Active" state for substrate cleavage, but with noticeably reduced conformational space compared with the wildtype. The other mutants hardly visited the "Active" state. The PS1 FAD mutants were found to reduce γ-secretase proteolytic activity by hindering APP residue L49 from proper orientation in the active site and/or disrupting the distance between the catalytic aspartates. Therefore, our findings provide mechanistic insights into how PS1 FAD mutations affect structural dynamics and enzyme-substrate interactions of γ-secretase and APP., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
22. Identification of the Aβ37/42 peptide ratio in CSF as an improved Aβ biomarker for Alzheimer's disease.
- Author
-
Liu L, Lauro BM, He A, Lee H, Bhattarai S, Wolfe MS, Bennett DA, Karch CM, Young-Pearse T, and Selkoe DJ
- Subjects
- Humans, Amyloid beta-Peptides, Amyloid Precursor Protein Secretases, tau Proteins, Peptide Fragments, Biomarkers, Alzheimer Disease pathology, Cognitive Dysfunction diagnosis
- Abstract
Introduction: Identifying CSF-based biomarkers for the β-amyloidosis that initiates Alzheimer's disease (AD) could provide inexpensive and dynamic tests to distinguish AD from normal aging and predict future cognitive decline., Methods: We developed immunoassays specifically detecting all C-terminal variants of secreted amyloid β-protein and identified a novel biomarker, the Aβ 37/42 ratio, that outperforms the canonical Aβ42/40 ratio as a means to evaluate the γ-secretase activity and brain Aβ accumulation., Results: We show that Aβ 37/42 can distinguish physiological and pathological status in (1) presenilin-1 mutant vs wild-type cultured cells, (2) AD vs control brain tissue, and (3) AD versus cognitively normal (CN) subjects in CSF, where 37/42 (AUC 0.9622) outperformed 42/40 (AUC 0.8651) in distinguishing CN from AD., Discussion: We conclude that the Aβ 37/42 ratio sensitively detects presenilin/γ-secretase dysfunction and better distinguishes CN from AD than Aβ42/40 in CSF. Measuring this novel ratio alongside promising phospho-tau analytes may provide highly discriminatory fluid biomarkers for AD., (© 2022 the Alzheimer's Association.)
- Published
- 2023
- Full Text
- View/download PDF
23. Cancer Hazard Evaluations for Contemporary Needs: Highlights From New National Toxicology Program Evaluations and Methodological Advancements.
- Author
-
Lunn RM, Mehta SS, Jahnke GD, Wang A, Wolfe MS, and Berridge BR
- Subjects
- Animals, Humans, Program Evaluation, Dichloroacetic Acid, Carcinogens toxicity, Neoplasms epidemiology, Neoplasms prevention & control
- Abstract
The National Toxicology Program strives to raise awareness of cancer hazards in our environment. Identifying cancer hazards is key to primary prevention, informing public health decision making, and decreasing the global cancer burden. In December 2021, the US congressionally mandated 15th Report on Carcinogens was released, adding 8 new substances to the cumulative report. Chronic infection with Helicobacter pylori is listed as "known to be a human carcinogen." Antimony trioxide and 6 haloacetic acids found as water disinfection by-products-dichloroacetic acid, dibromoacetic acid, bromochloroacetic acid, tribromoacetic acid, bromodichloroacetic acid, chlorodibromoacetic acid-are listed as "reasonably anticipated to be a human carcinogen." A new dashboard provides interactive visualization and interrogation of the 256 listed substances, their uses, and associated cancers. Also, the National Toxicology Program recently published a Cancer Hazard Assessment Report on exposure scenarios associated with circadian disruption, concluding that persistent night shift work can cause breast cancer and certain lighting conditions may cause cancer. As highlighted in these reports and evaluations, we are evolving our approaches to meet contemporary challenges. These approaches include focusing on real-world exposures and advancing our methods to address challenges in cancer hazard assessments (eg, developing more structured approaches to evaluate mechanistic data and incorporating read-across approaches to assess chemicals lacking adequate human or animal cancer data). To promote public health, we provide information on environmental health disparities and disease prevention. Building on these efforts, we aim to continue our contributions to the war on cancer, declared 50 years ago., (© The Author(s) 2022. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
24. γ-Secretase as a drug target for familial Alzheimer's disease: the road less traveled.
- Author
-
Wolfe MS
- Subjects
- Amyloid beta-Peptides, Humans, Mutation, Alzheimer Disease drug therapy, Amyloid Precursor Protein Secretases
- Published
- 2022
- Full Text
- View/download PDF
25. In-Depth Characterization of Endo-Lysosomal Aβ in Intact Neurons.
- Author
-
McKendell AK, Houser MCQ, Mitchell SPC, Wolfe MS, Berezovska O, and Maesako M
- Subjects
- Amyloid beta-Peptides, Animals, Lysosomes metabolism, Mice, Neurons metabolism, Alzheimer Disease, Amyloid Precursor Protein Secretases metabolism
- Abstract
Amyloid-beta (Aβ) peptides are produced within neurons. Some peptides are released into the brain parenchyma, while others are retained inside the neurons. However, the detection of intracellular Aβ remains a challenge since antibodies against Aβ capture Aβ and its precursor proteins (i.e., APP and C99). To overcome this drawback, we recently developed 1) the C99 720-670 biosensor for recording γ-secretase activity and 2) a unique multiplexed immunostaining platform that enables the selective detection of intracellular Aβ with subcellular resolution. Using these new assays, we showed that C99 is predominantly processed by γ-secretase in late endosomes and lysosomes, and intracellular Aβ is enriched in the same subcellular loci in intact neurons. However, the detailed properties of Aβ in the acidic compartments remain unclear. Here, we report using fluorescent lifetime imaging microscopy (FLIM) that intracellular Aβ includes both long Aβ intermediates bound to γ-secretase and short peptides dissociated from the protease complex. Surprisingly, our results also suggest that the dissociated Aβ is bound to the glycoproteins on the inner membrane of lysosomes. Furthermore, we show striking cell-to-cell heterogeneity in intracellular Aβ levels in primary neurons and APP transgenic mouse brains. These findings provide a basis for the further investigation of the role(s) of intracellular Aβ and its relevance to Alzheimer's disease (AD).
- Published
- 2022
- Full Text
- View/download PDF
26. Structure and mechanism of the γ-secretase intramembrane protease complex.
- Author
-
Wolfe MS and Miao Y
- Subjects
- Cell Membrane metabolism, Cryoelectron Microscopy, Receptors, Notch metabolism, Amyloid Precursor Protein Secretases metabolism, Amyloid beta-Protein Precursor chemistry
- Abstract
γ-Secretase is a membrane protein complex that proteolyzes within the transmembrane domain of >100 substrates, including those derived from the amyloid precursor protein and the Notch family of cell surface receptors. The nine-transmembrane presenilin is the catalytic component of this aspartyl protease complex that carries out hydrolysis in the lipid bilayer. Advances in cryoelectron microscopy have led to the elucidation of the structure of the γ-secretase complex at atomic resolution. Recently, structures of the enzyme have been determined with bound APP- or Notch-derived substrates, providing insight into the nature of substrate recognition and processing. Molecular dynamics simulations of substrate-bound enzymes suggest dynamic mechanisms of intramembrane proteolysis. Structures of the enzyme bound to small-molecule inhibitors and modulators have also been solved, setting the stage for rational structure-based drug discovery targeting γ-secretase., (Copyright © 2022 Elsevier Ltd. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
27. Correction to "Mechanism of Tripeptide Trimming of Amyloid β-Peptide 49 by γ-Secretase".
- Author
-
Bhattarai A, Devkota S, Do HN, Wang J, Bhattarai S, Wolfe MS, and Miao Y
- Published
- 2022
- Full Text
- View/download PDF
28. Mechanism of Tripeptide Trimming of Amyloid β-Peptide 49 by γ-Secretase.
- Author
-
Bhattarai A, Devkota S, Do HN, Wang J, Bhattarai S, Wolfe MS, and Miao Y
- Subjects
- Humans, Amyloid beta-Peptides metabolism, Amyloid Precursor Protein Secretases metabolism, Alzheimer Disease metabolism, Amyloid beta-Protein Precursor metabolism
- Abstract
The membrane-embedded γ-secretase complex processively cleaves within the transmembrane domain of amyloid precursor protein (APP) to produce 37-to-43-residue amyloid β-peptides (Aβ) of Alzheimer's disease (AD). Despite its importance in pathogenesis, the mechanism of processive proteolysis by γ-secretase remains poorly understood. Here, mass spectrometry and Western blotting were used to quantify the efficiency of tripeptide trimming of wild-type (WT) and familial AD (FAD) mutant Aβ49. In comparison to WT Aβ49, the efficiency of tripeptide trimming was similar for the I45F, A42T, and V46F Aβ49 FAD mutants but substantially diminished for the I45T and T48P mutants. In parallel with biochemical experiments, all-atom simulations using a novel peptide Gaussian accelerated molecular dynamics (Pep-GaMD) method were applied to investigate the tripeptide trimming of Aβ49 by γ-secretase. The starting structure was the active γ-secretase bound to Aβ49 and APP intracellular domain (AICD), as generated from our previous study that captured the activation of γ-secretase for the initial endoproteolytic cleavage of APP (Bhattarai, A., ACS Cent. Sci. 2020, 6, 969-983). Pep-GaMD simulations captured remarkable structural rearrangements of both the enzyme and substrate, in which hydrogen-bonded catalytic aspartates and water became poised for tripeptide trimming of Aβ49 to Aβ46. These structural changes required a positively charged N-terminus of endoproteolytic coproduct AICD, which could dissociate during conformational rearrangements of the protease and Aβ49. The simulation findings were highly consistent with biochemical experimental data. Taken together, our complementary biochemical experiments and Pep-GaMD simulations have enabled elucidation of the mechanism of tripeptide trimming of Aβ49 by γ-secretase.
- Published
- 2022
- Full Text
- View/download PDF
29. Verteporfin is a substrate-selective γ-secretase inhibitor that binds the amyloid precursor protein transmembrane domain.
- Author
-
Castro MA, Parson KF, Beg I, Wilkinson MC, Nurmakova K, Levesque I, Voehler MW, Wolfe MS, Ruotolo BT, and Sanders CR
- Subjects
- Amyloid beta-Peptides metabolism, Enzyme Inhibitors metabolism, Enzyme Inhibitors pharmacology, Humans, Membrane Proteins metabolism, Protein Domains, Receptors, Notch metabolism, Amyloid Precursor Protein Secretases antagonists & inhibitors, Amyloid Precursor Protein Secretases metabolism, Amyloid beta-Protein Precursor metabolism, Verteporfin metabolism, Verteporfin pharmacology
- Abstract
This work reports substrate-selective inhibition of a protease with broad substrate specificity based on direct binding of a small-molecule inhibitor to the substrate. The target for these studies was γ-secretase protease, which cleaves dozens of different single-span membrane protein substrates, including both the C99 domain of the human amyloid precursor protein and the Notch receptor. Substrate-specific inhibition of C99 cleavage is desirable to reduce production of the amyloid-β polypeptide without inhibiting Notch cleavage, a major source of toxicity associated with broad specificity γ-secretase inhibitors. In order to identify a C99-selective inhibitors of the human γ-secretase, we conducted an NMR-based screen of FDA-approved drugs against C99 in model membranes. From this screen, we identified the small-molecule verteporfin with these properties. We observed that verteporfin formed a direct 1:1 complex with C99, with a K
D of 15-47 μM (depending on the membrane mimetic used), and that it did not bind the transmembrane domain of the Notch-1 receptor. Biochemical assays showed that direct binding of verteporfin to C99 inhibits γ-secretase cleavage of C99 with IC50 values in the range of 15-164 μM, while Notch-1 cleavage was inhibited only at higher concentrations, and likely via a mechanism that does not involve binding to Notch-1. This work documents a robust NMR-based approach to discovery of small-molecule binders to single-span membrane proteins and confirmed that it is possible to inhibit γ-secretase in a substrate-specific manner., Competing Interests: Conflict of interest The authors declare that they have no conflicts of interest with the contents of this article., (Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
30. Evaluation of a semi-automated data extraction tool for public health literature-based reviews: Dextr.
- Author
-
Walker VR, Schmitt CP, Wolfe MS, Nowak AJ, Kulesza K, Williams AR, Shin R, Cohen J, Burch D, Stout MD, Shipkowski KA, and Rooney AA
- Subjects
- Animals, Review Literature as Topic, Software, Machine Learning, Public Health
- Abstract
Introduction: There has been limited development and uptake of machine-learning methods to automate data extraction for literature-based assessments. Although advanced extraction approaches have been applied to some clinical research reviews, existing methods are not well suited for addressing toxicology or environmental health questions due to unique data needs to support reviews in these fields., Objectives: To develop and evaluate a flexible, web-based tool for semi-automated data extraction that: 1) makes data extraction predictions with user verification, 2) integrates token-level annotations, and 3) connects extracted entities to support hierarchical data extraction., Methods: Dextr was developed with Agile software methodology using a two-team approach. The development team outlined proposed features and coded the software. The advisory team guided developers and evaluated Dextr's performance on precision, recall, and extraction time by comparing a manual extraction workflow to a semi-automated extraction workflow using a dataset of 51 environmental health animal studies., Results: The semi-automated workflow did not appear to affect precision rate (96.0% vs. 95.4% manual, p = 0.38), resulted in a small reduction in recall rate (91.8% vs. 97.0% manual, p < 0.01), and substantially reduced the median extraction time (436 s vs. 933 s per study manual, p < 0.01) compared to a manual workflow., Discussion: Dextr provides similar performance to manual extraction in terms of recall and precision and greatly reduces data extraction time. Unlike other tools, Dextr provides the ability to extract complex concepts (e.g., multiple experiments with various exposures and doses within a single study), properly connect the extracted elements within a study, and effectively limit the work required by researchers to generate machine-readable, annotated exports. The Dextr tool addresses data-extraction challenges associated with environmental health sciences literature with a simple user interface, incorporates the key capabilities of user verification and entity connecting, provides a platform for further automation developments, and has the potential to improve data extraction for literature reviews in this and other fields., (Copyright © 2021. Published by Elsevier Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
31. Presenilin/γ-Secretase Activity Is Located in Acidic Compartments of Live Neurons.
- Author
-
Maesako M, Houser MCQ, Turchyna Y, Wolfe MS, and Berezovska O
- Subjects
- Animals, Female, Male, Mice, Amyloid Precursor Protein Secretases metabolism, Amyloid beta-Protein Precursor metabolism, Endosomes metabolism, Lysosomes metabolism, Neurons metabolism, Presenilins metabolism
- Abstract
Presenilin (PSEN)/γ-secretase is a protease complex responsible for the proteolytic processing of numerous substrates. These substrates include the amyloid precursor protein (APP), the cleavage of which by γ-secretase results in the production of β-amyloid (Aβ) peptides. However, exactly where within the neuron γ-secretase processes APP C99 to generate Aβ and APP intracellular domain (AICD) is still not fully understood. Here, we employ novel Förster resonance energy transfer (FRET)-based multiplexed imaging assays to directly "visualize" the subcellular compartment(s) in which γ-secretase primarily cleaves C99 in mouse cortex primary neurons (from both male and female embryos). Our results demonstrate that γ-secretase processes C99 mainly in LysoTracker-positive low-pH compartments. Using a new immunostaining protocol which distinguishes Aβ from C99, we also show that intracellular Aβ is significantly accumulated in the same subcellular loci. Furthermore, we found functional correlation between the endo-lysosomal pH and cellular γ-secretase activity. Taken together, our findings are consistent with Aβ being produced from C99 by γ-secretase within acidic compartments such as lysosomes and late endosomes in living neurons. SIGNIFICANCE STATEMENT Alzheimer's disease (AD) genetics and histopathology highlight the importance of amyloid precursor protein (APP) processing by γ-secretase in pathogenesis. For the first time, this study has enabled us to directly "visualize" that γ-secretase processes C99 mainly in acidic compartments such as late endosomes and lysosomes in live neurons. Furthermore, we uncovered that intracellular β-amyloid (Aβ) is significantly accumulated in the same subcellular loci. Emerging evidence proposes the great importance of the endo-lysosomal pathway in mechanisms of misfolded proteins propagation (e.g., Tau, α-Syn). Therefore, the predominant processing of C99 and enrichment of Aβ in late endosomes and lysosomes may be critical events in the molecular cascade leading to AD., (Copyright © 2022 the authors.)
- Published
- 2022
- Full Text
- View/download PDF
32. Discovery of aryl aminothiazole γ-secretase modulators with novel effects on amyloid β-peptide production.
- Author
-
Bhattarai S, Liu L, and Wolfe MS
- Subjects
- Dose-Response Relationship, Drug, HEK293 Cells, Humans, Molecular Structure, Structure-Activity Relationship, Thiazoles chemistry, Amyloid Precursor Protein Secretases metabolism, Amyloid beta-Peptides biosynthesis, Drug Discovery, Thiazoles pharmacology
- Abstract
A series of analogs based on a prototype aryl aminothiazole γ-secretase modulator (GSM) were synthesized and tested for their effects on the profile of 37-to-42-residue amyloid β-peptides (Aβ), generated through processive proteolysis of precursor protein substrate by γ-secretase. Certain substitutions on the terminal aryl D ring resulted in an altered profile of Aβ production compared to that seen with the parent molecule. Small structural changes led to concentration-dependent increases in Aβ37 and Aβ38 production without parallel decreases in their precursors Aβ40 and Aβ42, respectively. The new compounds therefore apparently also stimulate carboxypeptidase trimming of Aβ peptides ≥ 43 residues, providing novel chemical tools for mechanistic studies of processive proteolysis by γ-secretase., (Copyright © 2021 Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
33. Design of Transmembrane Mimetic Structural Probes to Trap Different Stages of γ-Secretase-Substrate Interaction.
- Author
-
Bhattarai S, Devkota S, and Wolfe MS
- Subjects
- Amyloid Precursor Protein Secretases chemistry, Amyloid beta-Protein Precursor chemistry, Cryoelectron Microscopy, Humans, Models, Molecular, Substrate Specificity, Amyloid Precursor Protein Secretases metabolism, Amyloid beta-Protein Precursor metabolism
- Abstract
The transmembrane domain (TMD) of the amyloid precursor protein of Alzheimer's disease is cut processively by γ-secretase through endoproteolysis and tricarboxypeptidase "trimming". We recently developed a prototype substrate TMD mimetic for structural analysis-composed of a helical peptide inhibitor linked to a transition-state analogue-that simultaneously engages a substrate exosite and the active site and is pre-organized to trap the carboxypeptidase transition state. Here, we developed variants of this prototype designed to allow visualization of transition states for endoproteolysis, TMD helix unwinding, and lateral gating of the substrate, identifying potent inhibitors for each class. These TMD mimetics exhibited non-competitive inhibition and occupy both the exosite and the active site, as demonstrated by inhibitor cross-competition experiments and photoaffinity probe binding assays. The new probes should be important structural tools for trapping different stages of substrate recognition and processing via ongoing cryo-electron microscopy with γ-secretase, ultimately aiding rational drug design.
- Published
- 2021
- Full Text
- View/download PDF
34. Targeting γ-Secretase for Familial Alzheimer's Disease.
- Author
-
Wolfe MS
- Abstract
Familial Alzheimer's disease (FAD) is a rare early-onset genetic form of a common dementia of old age. Striking in middle age, FAD is caused by missense mutations in three genes: APP (encoding the amyloid precursor protein) and PSEN1 and PSEN2 (encoding presenilin-1 and presenilin-2). APP is proteolytically processed successively by β-secretase and γ-secretase to produce the amyloid β-peptide (Aβ). Presenilin is the catalytic component of γ-secretase, a membrane-embedded aspartyl protease complex that cleaves APP within its single transmembrane domain to produce Aβ of varying lengths. Thus, all FAD mutations are found in the substrate and the enzyme that produce Aβ. The 42-residue variant Aβ42 has been the primary focus of Alzheimer drug discovery for over two decades, as this particular peptide is highly prone to aggregation, is the major protein deposited in the characteristic cerebral plaques of Alzheimer's disease, and is proportionately elevated in FAD. Despite extensive efforts, all agents targeting Aβ and Aβ42 have failed in the clinic, including γ-secretase inhibitors, leading to questioning of the amyloid hypothesis of Alzheimer pathogenesis. However, processing of the APP transmembrane domain by γ-secretase is complex, involving initial endoproteolysis followed by successive carboxypeptidase trimming steps to secreted Aβ peptides such as Aβ42. Recent findings reveal that FAD mutations in PSEN1 and in APP result in deficient trimming of initially formed long Aβ peptides. A logical drug discovery strategy for FAD could therefore involve the search for compounds that rescue this deficient carboxypeptidase activity. The rare early-onset FAD arguably presents a simpler path to developing effective therapeutics compared to the much more complex heterogeneous sporadic Alzheimer's disease., Competing Interests: Conflict of Interest The author declares no conflict of interest.
- Published
- 2021
- Full Text
- View/download PDF
35. Probing Mechanisms and Therapeutic Potential of γ-Secretase in Alzheimer's Disease.
- Author
-
Wolfe MS
- Subjects
- Alzheimer Disease metabolism, Amyloid Precursor Protein Secretases genetics, Amyloid Precursor Protein Secretases metabolism, Animals, Enzyme Inhibitors chemistry, Humans, Molecular Conformation, Neuroprotective Agents chemistry, Alzheimer Disease drug therapy, Amyloid Precursor Protein Secretases antagonists & inhibitors, Enzyme Inhibitors pharmacology, Neuroprotective Agents pharmacology
- Abstract
The membrane-embedded γ-secretase complex carries out hydrolysis within the lipid bilayer in proteolyzing nearly 150 different membrane protein substrates. Among these substrates, the amyloid precursor protein (APP) has been the most studied, as generation of aggregation-prone amyloid β-protein (Aβ) is a defining feature of Alzheimer's disease (AD). Mutations in APP and in presenilin, the catalytic component of γ-secretase, cause familial AD, strong evidence for a pathogenic role of Aβ. Substrate-based chemical probes-synthetic peptides and peptidomimetics-have been critical to unraveling the complexity of γ-secretase, and small drug-like inhibitors and modulators of γ-secretase activity have been essential for exploring the potential of the protease as a therapeutic target for Alzheimer's disease. Such chemical probes and therapeutic prototypes will be reviewed here, with concluding commentary on the future directions in the study of this biologically important protease complex and the translation of basic findings into therapeutics.
- Published
- 2021
- Full Text
- View/download PDF
36. Mutations in the Amyloid-β Protein Precursor Reduce Mitochondrial Function and Alter Gene Expression Independent of 42-Residue Amyloid-β Peptide.
- Author
-
Pope CA, Wilkins HM, Swerdlow RH, and Wolfe MS
- Subjects
- Alzheimer Disease pathology, Brain pathology, Cell Line, Tumor, Gene Expression, Humans, Mitochondria metabolism, Neuroblastoma pathology, Neurons metabolism, Oxygen Consumption, Alzheimer Disease genetics, Amyloid Precursor Protein Secretases metabolism, Amyloid beta-Peptides metabolism, Amyloid beta-Protein Precursor genetics, Mutation, Missense genetics, Peptide Fragments metabolism
- Abstract
Background: Dominant missense mutations in the amyloid-β protein precursor (AβPP) cause early-onset familial Alzheimer's disease (FAD) and are associated with changes in the production or properties of the amyloid-β peptide (Aβ), particularly of the 42-residue variant (Aβ42) that deposits in the Alzheimer's disease (AD) brain. Recent findings, however, show that FAD mutations in AβPP also lead to increased production of longer Aβ variants of 45-49 residues in length., Objective: We aimed to test neurotoxicity of Aβ42 vis-á-vis longer variants, focusing specifically on mitochondrial function, as dysfunctional mitochondria are implicated in the pathogenesis of AD., Methods: We generated SH-SY5Y human neuroblastoma cells stably expressing AβPP mutations that lead to increased production of long Aβ peptides with or without Aβ42. These AβPP-expressing cells were tested for oxygen consumption rates (OCR) under different conditions designed to interrogate mitochondrial function. These cell lines were also examined for expression of genes important for mitochondrial or neuronal structure and function., Results: The mutant AβPP-expressing cells showed decreased basal OCRs as well as decreased OCRs associated with mitochondrial ATP production, even more so in the absence of Aβ42 production. Moreover, mutant AβPP-expressing cells producing longer forms of Aβ displayed altered expression of certain mitochondrial- and neuronal-associated genes, whether or not Aβ42 was produced., Conclusion: These findings suggest that mutant AβPP can cause mitochondrial dysfunction that is associated with long Aβ but not with Aβ42.
- Published
- 2021
- Full Text
- View/download PDF
37. Familial Alzheimer's disease mutations in amyloid protein precursor alter proteolysis by γ-secretase to increase amyloid β-peptides of ≥45 residues.
- Author
-
Devkota S, Williams TD, and Wolfe MS
- Subjects
- Alzheimer Disease pathology, Amyloid beta-Peptides chemistry, Animals, CHO Cells, Cricetinae, Cricetulus, Humans, Mutation genetics, Protein Domains genetics, Proteolysis, Alzheimer Disease genetics, Amyloid Precursor Protein Secretases genetics, Amyloid beta-Peptides genetics, Amyloid beta-Protein Precursor genetics
- Abstract
Production of amyloid β-protein (Aβ) is carried out by the membrane-embedded γ-secretase complex. Mutations in the transmembrane domain of amyloid β-protein precursor (APP) associated with early-onset familial Alzheimer's disease (FAD) can alter the ratio of aggregation-prone 42-residue Aβ (Aβ42) to 40-residue Aβ (Aβ40). However, APP substrate is proteolyzed processively by γ-secretase along two pathways: Aβ49→Aβ46→Aβ43→Aβ40 and Aβ48→Aβ45→Aβ42→Aβ38. Effects of FAD mutations on each proteolytic step are unknown, largely due to difficulties in detecting and quantifying longer Aβ peptides. To address this, we carried out systematic and quantitative analyses of all tri- and tetrapeptide coproducts from proteolysis of wild-type and 14 FAD-mutant APP substrates by purified γ-secretase. These small peptides, including FAD-mutant forms, were detected by tandem mass spectrometry and quantified by establishing concentration curves for each of 32 standards. APP intracellular domain (AICD) coproducts were quantified by immunoblot, and the ratio of AICD products corresponding to Aβ48 and Aβ49 was determined by mass spectrometry. Levels of individual Aβ peptides were determined by subtracting levels of peptide coproducts associated with degradation from those associated with production. This method was validated for Aβ40 and Aβ42 by specific ELISAs and production of equimolar levels of Aβ and AICD. Not all mutant substrates led to increased Aβ42/40. However, all 14 disease-causing mutations led to inefficient processing of longer forms of Aβ ≥ 45 residues. In addition, the effects of certain mutations provided insight into the mechanism of processive proteolysis: intermediate Aβ peptides apparently remain bound for subsequent trimming and are not released and reassociated., Competing Interests: Conflict of interest The authors declare that they have no conflicts of interest with the contents of this article., (Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
38. Hydrophilic loop 1 of Presenilin-1 and the APP GxxxG transmembrane motif regulate γ-secretase function in generating Alzheimer-causing Aβ peptides.
- Author
-
Liu L, Lauro BM, Wolfe MS, and Selkoe DJ
- Subjects
- Alzheimer Disease genetics, Alzheimer Disease pathology, Amyloid beta-Protein Precursor chemistry, Amyloid beta-Protein Precursor genetics, Cells, Cultured, Genetic Predisposition to Disease, Humans, Mutation, Presenilin-1 chemistry, Presenilin-1 genetics, Protein Domains, Proteolysis, Substrate Specificity, Alzheimer Disease metabolism, Amyloid Precursor Protein Secretases metabolism, Amyloid beta-Peptides metabolism, Amyloid beta-Protein Precursor metabolism, Presenilin-1 metabolism
- Abstract
γ-Secretase is responsible for the proteolysis of amyloid precursor protein (APP) into amyloid-beta (Aβ) peptides, which are centrally implicated in the pathogenesis of Alzheimer's disease (AD). The biochemical mechanism of how processing by γ-secretase is regulated, especially as regards the interaction between enzyme and substrate, remains largely unknown. Here, mutagenesis reveals that the hydrophilic loop-1 (HL-1) of presenilin-1 (PS1) is critical for both γ-secretase step-wise cleavages (processivity) and its allosteric modulation by heterocyclic γ-modulatory compounds. Systematic mutagenesis of HL-1, including all of its familial AD mutations and additional engineered variants, and quantification of the resultant Aβ products show that HL-1 is necessary for proper sequential γ-secretase processivity. We identify Y106, L113, and Y115 in HL-1 as key targets for heterocyclic γ-secretase modulators (GSMs) to stimulate processing of pathogenic Aβ peptides. Further, we confirm that the GxxxG domain in the APP transmembrane region functions as a critical substrate motif for γ-secretase processivity: a G29A substitution in APP-C99 mimics the beneficial effects of GSMs. Together, these findings provide a molecular basis for the structural regulation of γ-processivity by enzyme and substrate, facilitating the rational design of new GSMs that lower AD-initiating amyloidogenic Aβ peptides., Competing Interests: Conflict of interest The authors declare that they have no conflicts of interest with the contents of this article., (Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
39. Unraveling the complexity of γ-secretase.
- Author
-
Wolfe MS
- Subjects
- Humans, Alzheimer Disease genetics, Amyloid Precursor Protein Secretases metabolism
- Abstract
γ-Secretase was initially defined as a proteolytic activity that cleaves within the transmembrane of the amyloid precursor protein (APP) to produce the amyloid β-peptide of Alzheimer's disease. The discovery of mutations in APP and the presenilins associated with familial Alzheimer's disease and their effects on APP processing dovetailed with pharmacological studies on γ-secretase, leading to the revelation that presenilins are unprecedented membrane-embedded aspartyl proteases. Other members of what became known as the γ-secretase complex were subsequently identified. In parallel with these advances, connections between presenilins and Notch receptors essential to metazoan development became evident, resulting in the concurrent realization that γ-secretase also carries out intramembrane proteolysis of Notch as part of its signaling mechanism. Substantial progress has been made toward elucidating how γ-secretase carries out complex processing of transmembrane domains, how it goes awry in familial Alzheimer's disease, the scope of its substrates, and the atomic details of its structure. Critical questions remain for future study, toward further unraveling the complexity of this unique membrane-embedded proteolytic machine and its roles in biology and disease., Competing Interests: Declaration of Competing Interest The author declares no conflicts of interest., (Copyright © 2020 Elsevier Ltd. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
40. The increased use of diversity in cereal cropping requires more descriptive precision.
- Author
-
Wolfe MS and Ceccarelli S
- Subjects
- Crop Production, Crops, Agricultural classification, Crops, Agricultural genetics, Crops, Agricultural growth & development, Edible Grain classification, Edible Grain growth & development, Hybridization, Genetic, Plant Breeding, Selection, Genetic, Biodiversity, Edible Grain genetics
- Abstract
Background: Until 100 years ago, cereals were grown only as populations with varying amounts of genetic diversity both within and among different crops. However, since the nineteenth century, methods for isolating and reproducing monocultural varieties have become universal, particularly among larger producers, leading to widespread within-field genetic monotony. A range of approaches is now being used to increase genetic diversity within and among crops including bringing back into cultivation a range of populations using a variety of different names, such as old varieties, landraces, ancient grains, heritage varieties, heirloom varieties, and mixtures. The objective of this paper, which is the result of the First International Conference on Landraces (Bologna, July 2018), is to contribute to the more precise definition of the names that are used more frequently., Results: One early approach to increasing diversity among such monocultures was the use of variety mixtures, initially using static mixtures, meaning mixtures that were re-constituted from their original component varieties for each growing season. Some farmers, however, preferred to re-grow static mixtures from the harvested, and therefore selected, seed, thus converting them to what can be termed dynamic mixtures. Consequent natural inter-crossing within such dynamic mixtures means that, within a few seasons, following natural segregation, recombination and selection, they become populations. There is a wide body of literature on both static and dynamic mixtures, the discussion of which is beyond the scope of this paper. More recently, interest has been increasing in modern forms of evolutionary breeding of populations through direct hybridization of monocultural varieties followed by segregation and, commonly, natural selection, often in target production areas. As expected from evolutionary theory, such populations exhibit considerable resilience under variable environmental conditions, which is increasingly important in relation to the complexity of climate change., Conclusion: To help identify different approaches, and communicate information, definitions can be based on the approximate known historical age of the plant material in question and its genetic structure. © 2019 Society of Chemical Industry., (© 2019 Society of Chemical Industry.)
- Published
- 2020
- Full Text
- View/download PDF
41. Mechanisms of γ-Secretase Activation and Substrate Processing.
- Author
-
Bhattarai A, Devkota S, Bhattarai S, Wolfe MS, and Miao Y
- Abstract
Amyloid β-peptide, the principal component of characteristic cerebral plaques of Alzheimer's disease (AD), is produced through intramembrane proteolysis of the amyloid precursor protein (APP) by γ-secretase. Despite the importance in the pathogenesis of AD, the mechanisms of intramembrane proteolysis and substrate processing by γ-secretase remain poorly understood. Here, complementary all-atom simulations using a robust Gaussian accelerated molecular dynamics (GaMD) method and biochemical experiments were combined to investigate substrate processing of wildtype and mutant APP by γ-secretase. The GaMD simulations captured spontaneous activation of γ-secretase, with hydrogen bonded catalytic aspartates and water poised for proteolysis of APP at the ε cleavage site. Furthermore, GaMD simulations revealed that familial AD mutations I45F and T48P enhanced the initial ε cleavage between residues Leu49-Val50, while M51F mutation shifted the ε cleavage site to the amide bond between Thr48-Leu49. Detailed analysis of the GaMD simulations allowed us to identify distinct low-energy conformational states of γ-secretase, different secondary structures of the wildtype and mutant APP substrate, and important active-site subpockets for catalytic function of the enzyme. The simulation findings were highly consistent with experimental analyses of APP proteolytic products using mass spectrometry and Western blotting. Taken together, the GaMD simulations and biochemical experiments have enabled us to elucidate the mechanisms of γ-secretase activation and substrate processing, which should facilitate rational computer-aided drug design targeting this functionally important enzyme., Competing Interests: The authors declare no competing financial interest., (Copyright © 2020 American Chemical Society.)
- Published
- 2020
- Full Text
- View/download PDF
42. A focus on cross-purpose tools, automated recognition of study design in multiple disciplines, and evaluation of automation tools: a summary of significant discussions at the fourth meeting of the International Collaboration for Automation of Systematic Reviews (ICASR).
- Author
-
O'Connor AM, Glasziou P, Taylor M, Thomas J, Spijker R, and Wolfe MS
- Subjects
- Automation, Humans, Systematic Reviews as Topic, Research Design
- Abstract
The fourth meeting of the International Collaboration for Automation of Systematic Reviews (ICASR) was held 5-6 November 2019 in The Hague, the Netherlands. ICASR is an interdisciplinary group whose goal is to maximize the use of technology for conducting rapid, accurate, and efficient systematic reviews of scientific evidence. The group seeks to facilitate the development and acceptance of automated techniques for systematic reviews. In 2018, the major themes discussed were the transferability of automation tools (i.e., tools developed for other purposes that might be used by systematic reviewers), the automated recognition of study design in multiple disciplines and applications, and approaches for the evaluation of automation tools.
- Published
- 2020
- Full Text
- View/download PDF
43. Natural Selection Towards Wild-Type in Composite Cross Populations of Winter Wheat.
- Author
-
Knapp S, Döring TF, Jones HE, Snape J, Wingen LU, Wolfe MS, Leverington-Waite M, and Griffiths S
- Abstract
Most of our crops are grown in monoculture with single genotypes grown over wide acreage. An alternative approach, where segregating populations are used as crops, is an exciting possibility, but outcomes of natural selection upon this type of crop are not well understood. We tracked allelic frequency changes in evolving composite cross populations of wheat grown over 10 generations under organic and conventional farming. At three generations, each population was genotyped with 19 SSR and 8 SNP markers. The latter were diagnostic for major functional genes. Gene diversity was constant at SSR markers but decreased over time for SNP markers. Population differentiation between the four locations could not be detected, suggesting that organic vs. non-organic crop management did not drive allele frequency changes. However, we did see changes for genes controlling plant height and phenology in all populations independently and consistently. We interpret these changes as the result of a consistent natural selection towards wild-type. Independent selection for alleles that are associated with plant height suggests that competition for light was central, resulting in the predominance of stronger intraspecific competitors, and highlighting a potential trade-off between individual and population performance., (Copyright © 2020 Knapp, Döring, Jones, Snape, Wingen, Wolfe, Leverington-Waite and Griffiths.)
- Published
- 2020
- Full Text
- View/download PDF
44. Design of Substrate Transmembrane Mimetics as Structural Probes for γ-Secretase.
- Author
-
Bhattarai S, Devkota S, Meneely KM, Xing M, Douglas JT, and Wolfe MS
- Subjects
- Amyloid Precursor Protein Secretases metabolism, Catalytic Domain, HEK293 Cells, Humans, Kinetics, Molecular Docking Simulation, Peptidomimetics metabolism, Protease Inhibitors metabolism, Protein Binding, Protein Conformation, alpha-Helical, Amyloid Precursor Protein Secretases antagonists & inhibitors, Peptidomimetics chemistry, Protease Inhibitors chemistry
- Abstract
γ-Secretase is a membrane-embedded aspartyl protease complex central in biology and medicine. How this enzyme recognizes transmembrane substrates and catalyzes hydrolysis in the lipid bilayer is unclear. Inhibitors that mimic the entire substrate transmembrane domain and engage the active site should provide important tools for structural biology, yielding insight into substrate gating and trapping the protease in the active state. Here, we report transmembrane peptidomimetic inhibitors of the γ-secretase complex that contain an N-terminal helical peptide region that engages a substrate docking exosite and a C-terminal transition-state analog moiety targeted to the active site. Both regions are required for stoichiometric inhibition of γ-secretase. Moreover, enzyme inhibition kinetics and photoaffinity probe displacement experiments demonstrate that both the docking exosite and the active site are engaged by the bipartite inhibitors. The solution conformations of these potent transmembrane-mimetic inhibitors are similar to those of bound natural substrates, suggesting these probes are preorganized for high-affinity binding and should allow visualization of the active γ-secretase complex, poised for intramembrane proteolysis, by cryo-electron microscopy.
- Published
- 2020
- Full Text
- View/download PDF
45. Substrate recognition and processing by γ-secretase.
- Author
-
Wolfe MS
- Subjects
- Amyloid beta-Protein Precursor metabolism, Animals, Humans, Membrane Proteins metabolism, Receptors, Notch metabolism, Substrate Specificity, Amyloid Precursor Protein Secretases metabolism
- Abstract
The γ-secretase complex is composed of four membrane protein subunits, including presenilin as the catalytic component with aspartyl protease activity. The enzyme cleaves within the transmembrane domain of >70 different type I integral membrane proteins and has been dubbed "the proteasome of the membrane". The most studied substrates include the Notch family of receptors, involved in cell differentiation, and the amyloid precursor protein (APP), involved in the pathogenesis of Alzheimer's disease. A central mechanistic question is how γ-secretase recognizes helical transmembrane substrates and carries out processive proteolysis. Recent findings addressing substrate recognition and processing will be discussed, including the role of protease subunit nicastrin as a gatekeeper, the effects of Alzheimer-causing mutations in presenilin on processive proteolysis of APP, and evidence that three pockets in the active site (S1', S2', and S3') determine carboxypeptidase cleavage of substrate in intervals of three residues. This article is part of a Special Issue entitled: Molecular biophysics of membranes and membrane proteins., (Copyright © 2019 Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
46. Designed Helical Peptides as Functional Probes for γ-Secretase.
- Author
-
Philip AT, Devkota S, Malvankar S, Bhattarai S, Meneely KM, Williams TD, and Wolfe MS
- Subjects
- Alzheimer Disease genetics, Amino Acid Sequence, Aminoisobutyric Acids chemistry, Amyloid beta-Protein Precursor chemical synthesis, Amyloid beta-Protein Precursor genetics, Mass Spectrometry, Mutation, Peptide Fragments chemical synthesis, Peptide Fragments genetics, Protein Conformation, alpha-Helical, Proteolysis, Amyloid Precursor Protein Secretases chemistry, Amyloid beta-Protein Precursor chemistry, Peptide Fragments chemistry
- Abstract
γ-Secretase is a membrane-embedded aspartyl protease complex with presenilin as the catalytic component that cleaves within the transmembrane domain (TMD) of >90 known substrates, including the amyloid precursor protein (APP) of Alzheimer's disease. Processing by γ-secretase of the APP TMD produces the amyloid β-peptide (Aβ), including the 42-residue variant (Aβ42) that pathologically deposits in the Alzheimer brain. Complex proteolysis of APP substrate by γ-secretase involves initial endoproteolysis and subsequent carboxypeptidase trimming, resulting in two pathways of Aβ production: Aβ49 → Aβ46 → Aβ43 → Aβ40 and Aβ48 → Aβ45 → Aβ42 → Aβ38. Dominant mutations in APP and presenilin cause early onset familial Alzheimer's disease (FAD). Understanding how γ-secretase processing of APP is altered in FAD is essential for elucidating pathogenic mechanisms in FAD and developing effective therapeutics. To improve our understanding, we designed synthetic APP-based TMD substrates as convenient functional probes for γ-secretase. Installation of the helix-inducing residue α-aminoisobutyric acid provided full TMD helical substrates while also facilitating their synthesis and increasing the solubility of these highly hydrophobic peptides. Through mass spectrometric analysis of proteolytic products, synthetic substrates were identified that were processed in a manner that reproduced physiological processing of APP substrates. Validation of these substrates was accomplished through mutational variants, including the installation of two natural APP FAD mutations. These FAD mutations also resulted in increased levels of formation of Aβ-like peptides corresponding to Aβ45 and longer, raising the question of whether the levels of such long Aβ peptides are indeed increased and might contribute to FAD pathogenesis.
- Published
- 2019
- Full Text
- View/download PDF
47. Multiple BACE1 inhibitors abnormally increase the BACE1 protein level in neurons by prolonging its half-life.
- Author
-
Liu L, Lauro BM, Ding L, Rovere M, Wolfe MS, and Selkoe DJ
- Subjects
- Amyloid Precursor Protein Secretases genetics, Animals, Cell Culture Techniques, Enzyme-Linked Immunosorbent Assay, Half-Life, Humans, Mice, Alzheimer Disease metabolism, Amyloid Precursor Protein Secretases metabolism, Aspartic Acid Endopeptidases genetics, Imidazoles, Neurons metabolism, Spiro Compounds
- Abstract
Introduction: There is keen interest in elucidating the biological mechanisms underlying recent failures of β-site amyloid precursor protein-cleaving enzyme-1 (BACE1) inhibitors in Alzheimer's disease trials., Methods: We developed a highly sensitive and specific immunoassay for BACE1 in cell lines and iPSC-derived human neurons to systematically analyze the effects of eight clinically relevant BACE1 inhibitors., Results: Seven of 8 inhibitors elevated BACE1 protein levels. Among protease inhibitors tested, the elevation was specific to BACE1 inhibitors. The inhibitors did not increase BACE1 transcription but extended the protein's half-life. BACE1 became elevated at concentrations below the IC
50 for amyloid β (Aβ)., Discussion: Elevation of BACE1 by 7 of 8 BACE1 inhibitors raises new concerns about advancing such β-secretase inhibitors for AD. Chronic elevation could lead to intermittently uninhibited BACE1 when orally dosed inhibitors reach trough levels, abnormally increasing substrate processing. Compounds such as roburic acid that lower Aβ by dissociating β/γ secretase complexes are better candidates because they neither inhibit β- and γ-secretase nor increase BACE1 levels., (Copyright © 2019 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
48. Structure and Function of the γ-Secretase Complex.
- Author
-
Wolfe MS
- Subjects
- Alzheimer Disease genetics, Alzheimer Disease metabolism, Amyloid Precursor Protein Secretases chemistry, Amyloid Precursor Protein Secretases genetics, Amyloid beta-Peptides metabolism, Animals, Cell Membrane genetics, Cell Membrane metabolism, Cryoelectron Microscopy, Humans, Hydrolysis, Lipid Bilayers metabolism, Models, Molecular, Mutagenesis, Presenilin-1 chemistry, Presenilin-1 genetics, Presenilin-1 metabolism, Protein Conformation, Amyloid Precursor Protein Secretases metabolism
- Abstract
γ-Secretase is a membrane-embedded protease complex, with presenilin as the catalytic component containing two transmembrane aspartates in the active site. With more than 90 known substrates, the γ-secretase complex is considered "the proteasome of the membrane", with central roles in biology and medicine. The protease carries out hydrolysis within the lipid bilayer to cleave the transmembrane domain of the substrate multiple times before releasing secreted products. For many years, elucidation of γ-secretase structure and function largely relied on small-molecule probes and mutagenesis. Recently, however, advances in cryo-electron microscopy have led to the first detailed structures of the protease complex. Two new reports of structures of γ-secretase bound to membrane protein substrates provide great insight into the nature of substrate recognition and how Alzheimer's disease-causing mutations in presenilin might alter substrate binding and processing. These new structures offer a powerful platform for elucidating enzyme mechanisms, deciphering effects of disease-causing mutations, and advancing Alzheimer's disease drug discovery.
- Published
- 2019
- Full Text
- View/download PDF
49. Still moving toward automation of the systematic review process: a summary of discussions at the third meeting of the International Collaboration for Automation of Systematic Reviews (ICASR).
- Author
-
O'Connor AM, Tsafnat G, Gilbert SB, Thayer KA, Shemilt I, Thomas J, Glasziou P, and Wolfe MS
- Subjects
- Automation methods, Humans, Goals, Search Engine, Systematic Reviews as Topic, Workflow
- Abstract
The third meeting of the International Collaboration for Automation of Systematic Reviews (ICASR) was held 17-18 October 2017 in London, England. ICASR is an interdisciplinary group whose goal is to maximize the use of technology for conducting rapid, accurate, and efficient systematic reviews of scientific evidence. The group seeks to facilitate the development and widespread acceptance of automated techniques for systematic reviews. The meeting's conclusion was that the most pressing needs at present are to develop approaches for validating currently available tools and to provide increased access to curated corpora that can be used for validation. To that end, ICASR's short-term goals in 2018-2019 are to propose and publish protocols for key tasks in systematic reviews and to develop an approach for sharing curated corpora for validating the automation of the key tasks.
- Published
- 2019
- Full Text
- View/download PDF
50. A cellular complex of BACE1 and γ-secretase sequentially generates Aβ from its full-length precursor.
- Author
-
Liu L, Ding L, Rovere M, Wolfe MS, and Selkoe DJ
- Subjects
- Amyloid Precursor Protein Secretases antagonists & inhibitors, Amyloid Precursor Protein Secretases genetics, Animals, Aspartic Acid Endopeptidases antagonists & inhibitors, Aspartic Acid Endopeptidases genetics, Brain drug effects, Enzyme Inhibitors pharmacology, Female, HEK293 Cells, Humans, Induced Pluripotent Stem Cells enzymology, Male, Mice, Inbred C57BL, Multienzyme Complexes, Mutation, Presenilin-1 genetics, Presenilin-1 metabolism, Protein Binding, Proteolysis, Substrate Specificity, Amyloid Precursor Protein Secretases metabolism, Amyloid beta-Peptides metabolism, Amyloid beta-Protein Precursor metabolism, Aspartic Acid Endopeptidases metabolism, Brain enzymology
- Abstract
Intramembrane proteolysis of transmembrane substrates by the presenilin-γ-secretase complex is preceded and regulated by shedding of the substrate's ectodomain by α- or β-secretase. We asked whether β- and γ-secretases interact to mediate efficient sequential processing of APP, generating the amyloid β (Aβ) peptides that initiate Alzheimer's disease. We describe a hitherto unrecognized multiprotease complex containing active β- and γ-secretases. BACE1 coimmunoprecipitated and cofractionated with γ-secretase in cultured cells and in mouse and human brain. An endogenous high molecular weight (HMW) complex (∼5 MD) containing β- and γ-secretases and holo-APP was catalytically active in vitro and generated a full array of Aβ peptides, with physiological Aβ42/40 ratios. The isolated complex responded properly to γ-secretase modulators. Alzheimer's-causing mutations in presenilin altered the Aβ42/40 peptide ratio generated by the HMW β/γ-secretase complex indistinguishably from that observed in whole cells. Thus, Aβ is generated from holo-APP by a BACE1-γ-secretase complex that provides sequential, efficient RIP processing of full-length substrates to final products., (© 2019 Liu et al.)
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.